User profiles for "author:A M Scott"

Andrew M. Scott

- Verified email at onjcri.org.au - Cited by 32266

Anna Mae Scott

- Verified email at ndph.ox.ac.uk - Cited by 3178

[HTML][HTML] Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review

R Moynihan, S Sanders, ZA Michaleff, AM Scott… - BMJ open, 2021 - bmjopen.bmj.com
Objectives To determine the extent and nature of changes in utilisation of healthcare
services during COVID-19 pandemic. Design Systematic review. Eligibility Eligible studies …

Antibody therapy of cancer

AM Scott, JD Wolchok, LJ Old - Nature reviews cancer, 2012 - nature.com
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable
success in recent years. Antibody–drug conjugates are powerful new treatment options for …

Monoclonal antibodies in cancer therapy

AM Scott, JP Allison, JD Wolchok - Cancer immunity, 2012 - AACR
Monoclonal antibody-based treatment of cancer has been established as one of the most
successful therapeutic strategies for both hematologic malignancies and solid tumors in the …

Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q

AL Pusic, AF Klassen, AM Scott, JA Klok… - Plastic and …, 2009 - journals.lww.com
Background: Measuring patient-reported outcomes has become increasingly important in
cosmetic and reconstructive breast surgery. The objective of this study was to develop a new …

Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived …

BJ Tauro, DW Greening, RA Mathias, H Ji… - Methods, 2012 - Elsevier
Exosomes are 40–100nm extracellular vesicles that are released from a multitude of cell
types, and perform diverse cellular functions including intercellular communication, antigen …

[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

MS Hofman, L Emmett, S Sandhu, A Iravani… - The Lancet, 2021 - thelancet.com
Summary Background Lutetium-177 [177 Lu] Lu-PSMA-617 is a radiolabelled small
molecule that delivers β radiation to cells expressing prostate-specific membrane antigen …

[HTML][HTML] Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia

DS Ritchie, PJ Neeson, A Khot, S Peinert, T Tai… - Molecular Therapy, 2013 - cell.com
In a phase I study of autologous chimeric antigen receptor (CAR) anti-LeY T-cell therapy of
acute myeloid leukemia (AML), we examined the safety and postinfusion persistence of …

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

ID Davis, W Chen, H Jackson… - Proceedings of the …, 2004 - National Acad Sciences
NY-ESO-1 is a “cancer-testis” antigen expressed in many cancers. ISCOMATRIX is a
saponin-based adjuvant that induces antibody and T cell responses. We performed a …

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer

AM Scott, G Wiseman, S Welt, A Adjei, FT Lee… - Clinical cancer …, 2003 - AACR
Purpose: The purpose of this research was to determine the safety, immunogenicity,
pharmacokinetics, biodistribution, and tumor uptake of repeat infusions of a complementarity …

The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study

PJ Roach, R Francis, L Emmett, E Hsiao… - Journal of Nuclear …, 2018 - Soc Nuclear Med
68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional
imaging techniques in patients with prostate cancer. This prospective Australian multicenter …